LinkedInXFacebook
Subscribe
Orthopedics This Week
  • My Feed
  • |Posts
  • |Events
  • |MSK Innovations
  • |Power Rankings
  • |Masterclasses
  • |Technology Awards
  • Press Releases
  • |Advertising
  • |Job Board
  • Spine
  • ◆Joints
  • ◆Upper Extremities
  • ◆Foot & Ankle
  • ◆Sports Medicine
  • ◆Pain Mgmt
  • ◆Trauma
  • ◆Biologics
  • ◆Technology
  • ◆People
  • ◆Company News
  • ◆Legal & Regulatory
Home/Company News/Zimmer’s 2nd Try for Euro Biomet Merger Approval
Company News

Zimmer’s 2nd Try for Euro Biomet Merger Approval

February 9, 2015 1 min read Premium comments

Advertisement

Zimmer’s 2nd Try for Euro Biomet Merger Approval
Sources: Zimmer Holdings, Inc. and Biomet, Inc.
Secondary

Zimmer Holdings, Inc. has made a second proposal to the European Commission (EC) to get the regulators to approve their planned acquisition of Biomet, Inc.

The company announced on February 10, 2015, that the latest “revised remedy package” is generally consistent with the first divestiture proposal submitted to the EC in December. The original proposal called for the divestiture of one unicompartmental knee brand and one elbow brand in Europe and the divestiture of one total knee brand in two European Union (EU) countries.

The EC had effectively stopped the clock on its review of the deal on December 2, 2014 after some concerns. That’s when Zimmer offered the remedy package. The EC “market tested” the initial proposal and had some concerns. Hence, the revised proposal.

The company also said the formal deadline for the EC’s decision has been moved to May 26, 2015. However, the company still expects to close the deal before the end of March 2015. The company still needs approval from the U.S. Federal Trade Commission and Japan’s Fair Trade Commission to close the deal.

Zimmer noted in its announcement that it is “pleased with and encouraged by the progress to date with the overall regulatory process.”

React:

Discussion

14
DS
Dr. Sarah MitchellOrthopedic Surgeon · Mayo Clinic

This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?

8
JT
James Thornton, MDSpine Fellow · HSS

Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.

5
RP
R. PatelSports Medicine · Stanford

We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.

Join the conversation

Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.

Subscribe

Get Full Access

Read every OTW article and join member discussions for $24.99/month.

Get Full Access

Advertisement

Advertisement

Advertisement

Orthopedics This Week

The most trusted source in orthopedic industry news since 2005. Covering spine, joints, trauma, biologics, and the business of orthopedics.

A publication of RRY Publications, LLC

LinkedInXFacebook

Categories

  • Spine
  • Joints
  • Upper Extremities
  • Foot & Ankle
  • Sports Medicine
  • Pain Mgmt
  • Trauma
  • Biologics
  • Technology
  • People
  • Company News
  • Legal & Regulatory

Resources

  • Subscribe
  • Community Posts
  • Job Board
  • Press Release Opportunities
  • Power Rankings
  • About OTW
  • Advertise
  • Contact Us

Get Full Access

Unlimited articles, community posts, and Power Rankings.

Get Full Access

Plans start at $24.99/mo · Annual saves 20%

© 2026 Orthopedics This Week · RRY Publications, LLC

Privacy PolicyTerms of ServiceCookie Policy